Pre-scleroderma and new opportunities for preventive medicine
We read with great interest the Viewpoint by Alain Lescoat and colleagues1 in The Lancet Rheumatology, in which the authors highlighted the importance of deciphering the differential trajectories of individuals with pre-scleroderma. In our opinion, two points raised in this Viewpoint are essential. First, the absence of reliable data on the prevalence of pre-scleroderma (also due to the lack of consensus on its definition), and second, the absence of biomarkers of disease progression at early stages.